drugset / Trial / NCT06641024
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
Phase 1
Not yet recruiting
24 enrolled
Chongqing Precision Biotech Co., Ltd
Ruijin Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell formulation, and to preliminarily observe the efficacy of MC-1-50 cell formulation in subjects with relapsed/refractory CD19-positive B Cell Acute Lymphoblastic Leukemia.
Timeline
- Start
- 2024-11-01
- Primary completion
- 2027-11-01
- Completion
- 2039-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MC-1-50 | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | MC-1-50 | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | MC-1-50 | Cell therapy | 500000 cells/kg | Intravenous |